6:29 PM
 | 
Dec 10, 2015
 |  BC Extra  |  Company News

Alnylam provides pipeline update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it expects 10 "major clinical data readouts" next year and expects to have data from its first Phase III trial, a study of amyloidosis candidate patisiran ( ALN-TTR02), by YE17. The update came at an R&D day on Thursday, where Alnylam provided guidance on its ongoing clinical-stage programs and discussed its Alnylam 2020 plan.

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >